Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Stock Price Up 0.6% – Here’s Why

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) shares traded up 0.6% during mid-day trading on Thursday . The company traded as high as $94.06 and last traded at $93.01. Approximately 9,197 shares traded hands during trading, an increase of 30% from the average session volume of 7,091 shares. The stock had previously closed at $92.45.

Invesco Biotechnology & Genome ETF Stock Up 0.6%

The firm’s fifty day simple moving average is $84.71 and its 200-day simple moving average is $82.24. The company has a market cap of $288.33 million, a PE ratio of 20.44 and a beta of 0.70.

Institutional Investors Weigh In On Invesco Biotechnology & Genome ETF

A number of large investors have recently bought and sold shares of PBE. Northwestern Mutual Wealth Management Co. increased its position in Invesco Biotechnology & Genome ETF by 9,169.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 342,971 shares of the company’s stock worth $28,175,000 after buying an additional 339,271 shares in the last quarter. United Capital Financial Advisors LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at $5,946,000. Q3 Asset Management acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the fourth quarter valued at $1,431,000. Royal Bank of Canada increased its position in Invesco Biotechnology & Genome ETF by 22.3% during the 1st quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after purchasing an additional 13,767 shares in the last quarter. Finally, Dynamic Advisor Solutions LLC purchased a new stake in Invesco Biotechnology & Genome ETF during the 2nd quarter worth about $484,000.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.